First in the World! Arbele’s CDH17xCD3 Bispecific Antibody Received Clinical Trial Phase I Ethics Approval in Australia
On March 31, 2022, the clinical trial application of ARB202 received ethics approval in Australia.…
Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead candidate, volasertib, for use in treating pediatric rhabdomyosarcoma and other rare soft tissue sarcomas.
Read more: https://oncoheroes.com/press-releases-content/2020/10/14/volasertib-a-potential-new-treatment-for-rhabdomyosarcoma-receives-orphan-drug-designation-from-the-us-fda?ss_source=sscampaigns&ss_campaign_id=5f865ac9a6719d48ca49acb5&ss_email_id=5f873934dbbf7b61e83af6f5&ss_campaign_name=NEWS%21+FDA+grants+now+Orphan+Drug+Designation+to+volasertib&ss_campaign_sent_date=2020-10-14T17%3A46%3A09Z